2 unknown, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Unknown 2, Terminated 1 |
Follow GV1001 peptide: new trials by email Literature Review of GV1001 peptide trials Research Report on GV1001 peptide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients GV1001, Gemcitabine, Capecitabine - Pancreatic Cancer | Phase 3 | Unknown | Samsung Pharmaceutical Co., Ltd. | 148 | 2015-11-01 | 2016-11-22 |
| Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer GV1001, normal saline - Inoperable Stage III Non-small Cell Lung Cancer | Phase 3 | Unknown | Kael-GemVax Co., Ltd. | 600 | 2012-05-01 | 2012-04-19 |
| GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer GV1001, Gemcitabine (Chemotherapy) - Advanced Unresectable Pancreatic Cancer | Phase 3 | Terminated | Pharmexa A/S | 360 | 2006-06-01 | 2008-05-19 |
Pancreatic Neoplasms (2) · Adenocarcinoma (1)
Kael-GemVax Co., Ltd. (1) · Pharmexa A/S (1) · Samsung Pharmaceutical Co., Ltd. (1)
Australia (1) · Belgium (1) · Denmark (1) · France (1) · Ireland (1) · Italy (1) · Netherlands (1) · Norway (1) · Poland (1) · South Korea (1) · Spain (1) · Sweden (1) · United States (1)
Ask Aabenhus, MSc. (Pharm) (1) · Chang-Hwan Park, M.D. (1) · Eun Kwang Choi, M.D. (1) · Gwang Ha Kim, M.D. (1) · Ho Gak Kim, M.D. (1) · Ho Soon Choi, M.D. (1) · Hong Sik Lee, M.D. (1) · Jae Hee Cho, M.D. (1) · Jae Yong Cho, M.D. (1) · Joung-Ho Han, M.D. (1) · Kwang Hyuck Lee, M.D. (1) · Kyong Joo Lee, M.D. (1) · Seung Ok Lee, M.D. (1) · Si Young Song, M.D. (1) · Sinae Jeong (1)